The Burden of Health-Related Out-of-Pocket Cancer Costs in Canada: A Case-Control Study Using Linked Data.
cancer
cancer registry data
equity
health-related out-of-pocket cost burden
out-of-pocket costs
survey data
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
27 06 2022
27 06 2022
Historique:
received:
08
04
2022
revised:
02
06
2022
accepted:
20
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The burden of out-of-pocket costs among cancer patients/survivors in Canada is not well understood. The objective of this study was to examine the health-related out-of-pocket cost burden experienced by households with a cancer patient/survivor compared to those without, examine the components of health-related costs and determine who experiences a greater burden. This study used a data linkage between the Survey of Household Spending and the Canadian Cancer Registry to identify households with a cancer patient/survivor (cases) and those without (controls). The out-of-pocket burden (out-of-pocket costs measured relative to household income) and mean costs were described and regression analyses examined the characteristics associated with the household out-of-pocket burden and annual out-of-pocket costs. The health-related out-of-pocket cost burden and annual costs measured in households with a cancer patient/survivor were 3.08% (95% CI: 2.55-3.62%) and CAD 1600 (95% CI: 1456-1759), respectively, compared to a burden of 2.84% (95% CI: 2.31-3.38) and annual costs of CAD 1511 (95% CI: 1377-1659) measured in control households, respectively. Households with a colorectal cancer patient/survivor had a significantly higher out-of-pocket burden compared to controls (mean difference: 1.0%, 95% CI: 0.18, 0.46). Among both cases and controls, the lowest income quintile households experienced the highest health-related out-of-pocket cost burden. Within a universal health care system, it is still relevant to monitor health-related out-of-pocket spending that is not covered by existing insurance mechanisms; however, this is not routinely assessed in Canada. We demonstrate the feasibility of measuring such costs in households with a cancer patient/survivor using routinely collected data. While the burden and annual health-related out-of-pocket costs of households with a cancer patient/survivor were not significantly higher than control households in this study, the routine measurement of out-of-pocket costs in Canada could be systemized, providing a novel, system-level, equity-informed performance indicator, which is relevant for monitoring inequities in the burden of out-of-pocket costs.
Sections du résumé
BACKGROUND
The burden of out-of-pocket costs among cancer patients/survivors in Canada is not well understood. The objective of this study was to examine the health-related out-of-pocket cost burden experienced by households with a cancer patient/survivor compared to those without, examine the components of health-related costs and determine who experiences a greater burden.
DATA AND METHODS
This study used a data linkage between the Survey of Household Spending and the Canadian Cancer Registry to identify households with a cancer patient/survivor (cases) and those without (controls). The out-of-pocket burden (out-of-pocket costs measured relative to household income) and mean costs were described and regression analyses examined the characteristics associated with the household out-of-pocket burden and annual out-of-pocket costs.
RESULTS
The health-related out-of-pocket cost burden and annual costs measured in households with a cancer patient/survivor were 3.08% (95% CI: 2.55-3.62%) and CAD 1600 (95% CI: 1456-1759), respectively, compared to a burden of 2.84% (95% CI: 2.31-3.38) and annual costs of CAD 1511 (95% CI: 1377-1659) measured in control households, respectively. Households with a colorectal cancer patient/survivor had a significantly higher out-of-pocket burden compared to controls (mean difference: 1.0%, 95% CI: 0.18, 0.46). Among both cases and controls, the lowest income quintile households experienced the highest health-related out-of-pocket cost burden.
INTERPRETATION
Within a universal health care system, it is still relevant to monitor health-related out-of-pocket spending that is not covered by existing insurance mechanisms; however, this is not routinely assessed in Canada. We demonstrate the feasibility of measuring such costs in households with a cancer patient/survivor using routinely collected data. While the burden and annual health-related out-of-pocket costs of households with a cancer patient/survivor were not significantly higher than control households in this study, the routine measurement of out-of-pocket costs in Canada could be systemized, providing a novel, system-level, equity-informed performance indicator, which is relevant for monitoring inequities in the burden of out-of-pocket costs.
Identifiants
pubmed: 35877219
pii: curroncol29070359
doi: 10.3390/curroncol29070359
pmc: PMC9322389
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4541-4557Références
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Clin Lung Cancer. 2019 Jul;20(4):231-236
pubmed: 30797721
J Cancer Surviv. 2014 Mar;8(1):9-20
pubmed: 23975612
BMC Cancer. 2016 Oct 18;16(1):809
pubmed: 27756310
Curr Oncol. 2013 Jun;20(3):158-65
pubmed: 23737684
Palliat Med. 2015 Dec;29(10):908-17
pubmed: 26040484
J Psychosoc Oncol. 2018 Sep-Oct;36(5):582-596
pubmed: 30235067
CMAJ Open. 2018 Jan 4;6(1):E1-E10
pubmed: 29301745
Curr Oncol. 2011 Jan;18(1):e1-8
pubmed: 21331267
Support Care Cancer. 2020 Oct;28(10):4645-4665
pubmed: 32653957
CMAJ. 2020 Mar 2;192(9):E199-E205
pubmed: 32122974
Support Care Cancer. 2021 Jun;29(6):3377-3386
pubmed: 33403399
J Natl Cancer Inst. 2013 Feb 20;105(4):280-92
pubmed: 23349250
Oncology (Williston Park). 2013 Feb;27(2):80-1, 149
pubmed: 23530397
Support Care Cancer. 2019 Aug;27(8):2977-2986
pubmed: 30588549
EClinicalMedicine. 2020 Jan 31;20:100269
pubmed: 32300733
Lancet Oncol. 2012 Aug;13(8):790-801
pubmed: 22658655
Health Soc Care Community. 2015 Nov;23(6):605-18
pubmed: 25443659
Curr Oncol. 2021 Mar 15;28(2):1216-1248
pubmed: 33804288
Lancet. 2018 May 19;391(10134):2047-2058
pubmed: 29627161
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614